We take a look at directors buying and selling shares in their own company in our weekly column.
- Currys Chair buys 150k shares
- Non-execs acquire shares in British Land
- Non-exec Chair subscribes to e-therapeutics shares
Here’s why Director Dealings can play an important role in stock-picking
Currys Chair buys 150k shares
Currys LON:CURY Chair of the Board, Ian Dyson has purchased 150,000 shares at a price of 47.56p for a total consideration of £71,340. This follows a full year update from the retailer last week that saw a strengthening performance in the UK and Ireland is being offset by weakness in the Nordics. Adjusted pre-tax profit was down by almost 40% to £119m with group revenue off by 6%. Economic uncertainty together with high inflation and tough competition are weighing on the group’s outlook.
Currys share price was sitting at 49.94p at yesterday’s close, down 12% this year and down 30% over the last 12 months.
Non-execs acquire shares in British Land
British Land LON:BLND Non Executive Directors Tim Score, Irvinder Goodhew and Mark Aedy acquired 8,050, 4,708 and 2,935 shares respectively as full or partial satisfaction of their fees. The shares were priced at 310.54p each. Today’s high interest rate environment means that British Land, with its focus on the retail sector, has seen its share price hit lows not seen in two decades and the business is currently undergoing a transformation as it shifts its sector mix away from retail and towards logistics, life sciences, and office campuses.
British Land shares closed yesterday at 304.20, down 25% this year and down 34% over the last 12 months.
- UK Stock Market News: Experian, Currys, Fiinu
- Currys shares pick up speed going into Christmas: is it time to buy?
- Three Quick Facts: Currys, SThree, boohoo
Non-exec Chair subscribes to e-therapeutics shares
e-therapautics LON:ETX Chair Trevor Jones has subscribed to 34,830 ordinary shares at a price of 21.71p per share. The transaction represents 50% of Professor Jones’ fees net of tax, paid during the period from 31 December 2022 to 30 June 2023. The AIM listed biotech business final results in May were well received with CEO, Ali Mortazavi noting “We are now well-positioned to advance our pipeline of first-in-class preclinical RNAi candidates”. We haven’t covered the business before. Pop us a note in the comments below or on social media if you would like us to put together a report.
e-therapautics shares were trading at 20p at the close, up 18% for the year to date and up 14% over the last 12 months.
